Viewing Study NCT03703167

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 12:33 AM
Ignite Modification Date: 2026-03-02 @ 3:45 PM
Study NCT ID: NCT03703167
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-12-02
First Post: 2018-10-09
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL)
Sponsor: Memorial Sloan Kettering Cancer Center
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Primary Central Nervous System Lymphoma (PCNSL) View
None Secondary Central Nervous System Lymphoma (SCNSL) View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Ibrutinib View
None Rituximab View
None Lenalidomide View
None relapsed/refractory PCNSL View
None relapsed/refractory SCNSL View
None 18-432 View